AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
19 Jul 2016 02:15 PM
RNS
QTERN (saxa/dapa) EU approved for type-2 diabetes
18 Jul 2016 07:00 AM
RNS
TAGRISSO MET PRIMARY ENDPOINT IN PHASE III TRIAL
14 Jul 2016 12:07 PM
RNS
Second Price Monitoring Extn
14 Jul 2016 12:02 PM
RNS
Price Monitoring Extension
13 Jul 2016 07:00 AM
RNS
AZ resolves Faslodex patent litigation in the US
01 Jul 2016 05:30 PM
RNS
Total Voting Rights
01 Jul 2016 07:00 AM
RNS
AZ enters licensing agreements with LEO Pharma
28 Jun 2016 07:00 AM
RNS
Zavicefta approved in EU
23 Jun 2016 07:00 AM
RNS
AstraZeneca updates on Flumist vaccine in the US
14 Jun 2016 03:00 PM
RNS
Director/PDMR Shareholding
09 Jun 2016 07:03 AM
RNS
AZ agreement with Aspen for anaesthetics portfolio
03 Jun 2016 07:00 AM
RNS
AZ completes US licensing agreement with Ironwood
02 Jun 2016 07:00 AM
RNS
AZ LICENSES ZURAMPIC TO GRÜNENTHAL GMBH
01 Jun 2016 12:00 PM
RNS
Block listing Interim Review
01 Jun 2016 11:30 AM
RNS
Total Voting Rights
27 May 2016 12:36 PM
RNS
POSITIVE CHMP OPINION IN EU FOR SAXA/DAPA
27 May 2016 07:03 AM
RNS
Positive results from AstraZeneca Faslodex trial
27 May 2016 07:00 AM
RNS
AstraZeneca receives CRL from US FDA for ZS-9
23 May 2016 04:00 PM
RNS
Director/PDMR Shareholding
18 May 2016 07:00 AM
RNS
TOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL
17 May 2016 07:00 AM
RNS
POSITIVE BENRALIZUMAB RESULTS IN SEVERE ASTHMA
12 May 2016 07:00 AM
RNS
SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN US
11 May 2016 05:30 PM
RNS
Publication of Final Terms
09 May 2016 05:35 PM
RNS
Launch and pricing of EUR2.2bn bond issues
05 May 2016 03:00 PM
RNS
Publication of a Prospectus
03 May 2016 01:30 PM
RNS
Total Voting Rights
03 May 2016 07:01 AM
RNS
AstraZeneca completes divestment of Imdur
03 May 2016 07:00 AM
RNS
AZ COMPLETES ACQUISITION OF TAKEDA RESPIRATORY
29 Apr 2016 05:30 PM
RNS
Result of AGM
29 Apr 2016 12:46 PM
RNS
POSITIVE CHMP OPINION FOR CAZ AVI
29 Apr 2016 07:00 AM
RNS
AZN: 1st Quarter Results
28 Apr 2016 09:00 AM
RNS
Notice of Results
26 Apr 2016 09:29 AM
RNS
AZ enters US licensing agreement with Ironwood
26 Apr 2016 07:01 AM
RNS
BEVESPI AEROSPHERE APPROVED BY US FDA FOR COPD
08 Apr 2016 07:00 AM
RNS
AZ TO CONTINUE PIVOTAL ALZHEIMER'S CLINICAL TRIAL
01 Apr 2016 11:30 AM
RNS
Total Voting Rights
29 Mar 2016 07:00 AM
RNS
TAGRISSO APPROVED IN JAPAN FOR CANCER PATIENTS
24 Mar 2016 03:00 PM
RNS
Director/PDMR Shareholding
23 Mar 2016 07:00 AM
RNS
AZ reports results from Brilinta stroke trial
18 Mar 2016 10:30 AM
RNS
Notice of AGM
08 Mar 2016 06:29 PM
RNS
Filing of Form 20-F with SEC
08 Mar 2016 12:00 PM
RNS
Annual Financial Report
01 Mar 2016 02:30 PM
RNS
Total Voting Rights
29 Feb 2016 01:45 PM
RNS
AZ REPORTS TOP-LINE RESULT OF TREMELIMUMAB TRIAL
29 Feb 2016 07:59 AM
RNS
AZ enters licensing agreement with CMS for Plendil
26 Feb 2016 12:00 PM
RNS
Director/PDMR Shareholding
25 Feb 2016 08:57 AM
RNS
ACALABRUTINIB ORPHAN DRUG DESIGNATION RECOMMENDED
19 Feb 2016 07:05 AM
RNS
BRILIQUE APPROVED IN EU FOR HEART ATTACK PATIENTS
19 Feb 2016 07:00 AM
RNS
ZURAMPIC APPROVED IN EU FOR GOUT PATIENTS
17 Feb 2016 07:00 AM
RNS
Durvalumab granted BTD by FDA for cancer patients

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings